EU expands use of Roche's Pegasys in chronic hepatitis C

ZURICH Mon Mar 18, 2013 2:13am EDT

A logo of Swiss pharmaceutical company Roche is pictured in front of a company's building in Rotkreuz, April 12, 2012. REUTERS/Michael Buholzer

A logo of Swiss pharmaceutical company Roche is pictured in front of a company's building in Rotkreuz, April 12, 2012.

Credit: Reuters/Michael Buholzer

Related Topics

ZURICH (Reuters) - Roche said on Monday the European Medicines Agency (EMA) has expanded the approval of its drug Pegasys plus ribavirin for the treatment of chronic hepatitis C virus (HCV) to children five years of age and older.

The new label for the medicine that was first approved in the European Union over 10 years ago includes children five years and older who have not received treatment and have tested positive for HCV, Roche said in a statement.

Pegasys, in combination with the antiviral ribavirin, is the foundation of treatment for chronic HCV in adults, Roche said.

Mother-to-child transmission of HCV is the most common route of acquiring the infection in children with approximately 65,000 children estimated to live with chronic HCV in Europe, Roche said.

(Reporting by Silke Koltrowitz)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see
Comments (1)
jeff81201 wrote:
Pegasys with Ribavirin and telaprevir or boceprevir cause the following harms: decreased cognitive ability; depression; skin reactions – ie dry skin to psoriasis to Stevens-Johnson syndrome; damaged thyroid; arthritis; nervous and vascular system damage esp. in the toes, liver damage, other autoimmune disorders. It is chemotherapy.They whack your immune system, which is incredibly complex.

Many of the ill effects appear approximately 90 days after cessation of the drug, not just while one takes the drug. It seems that many patients ‘ immune systems start attacking their bodies as the drugs disappear from the body. Many patients will not make the connection between these late-arising symptoms and the drugs they quit three months ago.

A paper delivered at the AALDS national meeting in 2012 finds that those who are not cured end up developing worse liver damage sooner than if they had never taken the drug.

Stay away. Most people with Hep C live full natural lives with no symptoms. Hep C is not considered an STD and will not transfer except via blood to blood – it is VERY unlikely to pass via vaginal intercourse. Anal sex beware. DO NOT SHARE DRUG STRAWS with anybody.

The vast majority of general practitioners in the United States and even gastroenterologists are either unaware or maintain an ignorance about the side effects of this drug. These drugs almost certainly cause as much or more harm as they bring benefit. They are incredibly expensive, too. The medical treatment for severe side effects can also be very expensive, as can lost productivity.

No proper cost-benefit analysis has been done on these drugs, and they may well be a very bad odds play for one who has been diagnosed with Hep C.

BigPharma wants you to be scared about Hep C and do all they can to generate fear. A lot is unwarranted.

Mar 18, 2013 11:39am EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.